Mitotech S.A, a clinical-stage biotechnology company, today announced that its CEO, Natalia Perekhvatova, is invited to present during the LSX Investival Showcase 2023. The event will take place on November 13, 2023 in London, UK. “We look forward to LSX Investival event and to the opportunity for Mitotech to highlight its recent developments for treatments of Obesity and NASH,” said Natalia Perekhvatova.
About Mitotech S.A.
Mitotech S.A. is a Luxembourg-based late clinical stage biotechnology company developing drugs to treat the mitochondrial oxidative stress underlying metabolic and neurodegenerative disorders. Mitotech’s products are based on novel small molecules that inhibit ferroptosis within mitochondria.